Application of failure mode and effects analysis on hospital infection control for gynecological malignant tumor
10.3760/cma.j.issn.1674-2907.2019.34.010
- VernacularTitle:失效模式与效应分析法在控制妇科恶性肿瘤医院感染中的应用
- Author:
Fei HONG
1
;
Peihong WANG
;
Jin CAO
Author Information
1. 华中科技大学同济医学院附属协和医院妇产科,武汉 430000
- Keywords:
Gynecology;
Neoplasms;
Hospital infection;
Failure mode and effects analysis
- From:
Chinese Journal of Modern Nursing
2019;25(34):4450-4453
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effects of failure mode and effects analysis (FMEA) on hospital infection prevention for gynecological malignant tumor. Methods From January 2017 to December 2018, we selected 25 nurses and clinical staff of Department of Obstetrics and Gynecology in Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology as subjects by cluster sampling. And then, the gynecology hospital infection control group was built. Group members assessed the department's risk of hospital infection by FMEA and put forward improvements for the high risk factors. We compared the risk priority number (RPN) of gynecological malignant tumor patients, catheter-related bloodstream infection (CRBSI) and incidence of hospital infection before and after implementing FMEA. Results After implementing FMEA, the total score of RPN risk factors of gynecological malignant tumor patients decreased compared with those before implementation with statistical differences (P＜0.01). After implementing FMEA, a total of 276 gynecological malignant tumor patients were admitted. There were 22 of them with the hospital infection, less than that before implementation with statistical difference (χ2=4.473,P=0.034). There was no statistical difference in the incidence of CRBSI before and after implementation (P＞ 0.05). Conclusions FMEA has good application effects on hospital infection prevention for gynecological malignant tumor patients which can effectively reflect the weak link of hospital infection management to reduce the incidence of hospital infection of gynecological malignant tumor patients.
